Eiro Noemi, Fraile Maria, Fernández-Francos Silvia, Sánchez Rosario, Costa Luis A, Vizoso Francisco J
Unit Research, Fundación Hospital de Jove, Avda. Eduardo Castro 161, 33290, Gijón, Asturias, Spain.
Department of Surgery, Fundación Hospital de Jove, 33290, Gijón, Asturias, Spain.
Cell Biosci. 2021 Jun 10;11(1):109. doi: 10.1186/s13578-021-00620-6.
Mesenchymal stem cells (MSCs) play a central role in the intercellular signaling within the tumor microenvironment (TME), exchanging signals with cancer cells and tumor stromal cells, such as cancer-associated fibroblasts and inflammatory mononuclear cells. Research attributes both pro-tumor and anti-tumor actions to MSCs; however, evidence indicates that MSCs specific effect on the tumor depends on the source of the MSCs and the type of tumor. There are consistent data proving that MSCs from reproductive tissues, such as the uterus, umbilical cord or placenta, have potent anti-tumor effects and tropism towards tumor tissues. More interestingly, products derived from MSCs, such as secretome or extracellular vesicles, seem to reproduce the effects of their parental cells, showing a potential advantage for clinical treatments by avoiding the drawbacks associated with cell therapy. Given these perspectives, it appears necessary new research to optimize the production, safety and antitumor potency of the products derived from the MSCs suitable for oncological therapies.
间充质干细胞（MSCs）在肿瘤微环境（TME）中的细胞间信号传导中发挥核心作用，与癌细胞和肿瘤基质细胞（如癌症相关成纤维细胞和炎性单核细胞）交换信号。研究将促肿瘤和抗肿瘤作用都归因于MSCs；然而，有证据表明MSCs对肿瘤的特定作用取决于MSCs的来源和肿瘤类型。有一致的数据证明，来自生殖组织（如子宫、脐带或胎盘）的MSCs具有强大的抗肿瘤作用和对肿瘤组织的趋向性。更有趣的是，源自MSCs的产物，如分泌组或细胞外囊泡，似乎能重现其亲代细胞的作用，通过避免与细胞治疗相关的缺点，显示出临床治疗的潜在优势。鉴于这些观点，似乎有必要开展新的研究，以优化适用于肿瘤治疗的源自MSCs的产物的生产、安全性和抗肿瘤效力。
